These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 24183959)

  • 21. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.
    Amann JM; Lee JW; Roder H; Brahmer J; Gonzalez A; Schiller JH; Carbone DP
    J Thorac Oncol; 2010 Feb; 5(2):169-78. PubMed ID: 20035238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients.
    Wang Z; Wu YL; Zhang GC; Zhou Q; Xu CR; Guo AL
    Onkologie; 2008 Apr; 31(4):174-8. PubMed ID: 18418018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
    Tsai TH; Su KY; Wu SG; Chang YL; Luo SC; Jan IS; Yu CJ; Yu SL; Shih JY; Yang PC
    Eur Respir J; 2012 Mar; 39(3):677-84. PubMed ID: 21719485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR.
    Santis G; Angell R; Nickless G; Quinn A; Herbert A; Cane P; Spicer J; Breen R; McLean E; Tobal K
    PLoS One; 2011; 6(9):e25191. PubMed ID: 21949883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations.
    Chevrier S; Arnould L; Ghiringhelli F; Coudert B; Fumoleau P; Boidot R
    Int J Oncol; 2014 Sep; 45(3):1167-74. PubMed ID: 24990411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
    Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
    Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutation detection of epidermal growth factor receptor and KRAS genes using the smart amplification process version 2 from formalin-fixed, paraffin-embedded lung cancer tissue.
    Miyamae Y; Shimizu K; Mitani Y; Araki T; Kawai Y; Baba M; Kakegawa S; Sugano M; Kaira K; Lezhava A; Hayashizaki Y; Yamamoto K; Takeyoshi I
    J Mol Diagn; 2010 Mar; 12(2):257-64. PubMed ID: 20093389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of next-generation sequencing and mutation-specific platforms in clinical practice.
    Hinrichs JW; van Blokland WT; Moons MJ; Radersma RD; Radersma-van Loon JH; de Voijs CM; Rappel SB; Koudijs MJ; Besselink NJ; Willems SM; de Weger RA
    Am J Clin Pathol; 2015 Apr; 143(4):573-8. PubMed ID: 25780010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population.
    Fakhruddin N; Mahfouz R; Farhat F; Tfayli A; Abdelkhalik R; Jabbour M; Yehia L; Mahfoud Z; Zaatari G
    Oncol Rep; 2014 Nov; 32(5):2223-9. PubMed ID: 25120214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms.
    Jiang Y; Yuan Q; Fang Q
    J Cancer Res Clin Oncol; 2014 Jul; 140(7):1087-95. PubMed ID: 24728492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
    Kurtze I; Sonnemann J; Beck JF
    Oncol Rep; 2011 Apr; 25(4):1021-9. PubMed ID: 21271222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer.
    van Zandwijk N; Mathy A; Boerrigter L; Ruijter H; Tielen I; de Jong D; Baas P; Burgers S; Nederlof P
    Ann Oncol; 2007 Jan; 18(1):99-103. PubMed ID: 17060486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.
    Hata A; Katakami N; Fujita S; Kaji R; Imai Y; Takahashi Y; Nishimura T; Tomii K; Ishihara K
    J Thorac Oncol; 2010 Aug; 5(8):1197-200. PubMed ID: 20661086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.
    Beau-Faller M; Prim N; Ruppert AM; Nanni-Metéllus I; Lacave R; Lacroix L; Escande F; Lizard S; Pretet JL; Rouquette I; de Crémoux P; Solassol J; de Fraipont F; Bièche I; Cayre A; Favre-Guillevin E; Tomasini P; Wislez M; Besse B; Legrain M; Voegeli AC; Baudrin L; Morin F; Zalcman G; Quoix E; Blons H; Cadranel J
    Ann Oncol; 2014 Jan; 25(1):126-31. PubMed ID: 24285021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making.
    Campos-Parra AD; Zuloaga C; Manríquez ME; Avilés A; Borbolla-Escoboza J; Cardona A; Meneses A; Arrieta O
    Am J Clin Oncol; 2015 Feb; 38(1):33-40. PubMed ID: 23538866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes.
    Locatelli-Sanchez M; Couraud S; Arpin D; Riou R; Bringuier PP; Souquet PJ
    Lung; 2013 Oct; 191(5):491-9. PubMed ID: 23749122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy.
    Mazzoni F; Rotella V; Pratesi N; Boni L; Simi L; Orlando C; Comin CE; Maddau C; Di Costanzo F
    Tumori; 2011; 97(2):160-5. PubMed ID: 21617709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
    Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
    Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
    Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
    Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.